Novartis considers selling ophthalmology business: Report

Global healthcare company Novartis is in the early stages of preparing to sell its ophthalmology business, according to a Nov. 16 report from Bloomberg. 

The sale of the ophthalmology business alone could earn the company around $5 billion, according to the report. Private equity firms are already studying the business. 

Negotiations are ongoing, and if a sale happens it will likely happen in 2023, Bloomberg reported. 

In 2019, Novartis spun-off its Alcon eyecare business. In August, it spun-off its generic-drugs unit. 

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like